naproxen has been researched along with myelin oligodendrocyte glycoprotein (35-55) in 1 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (myelin oligodendrocyte glycoprotein (35-55)) | Trials (myelin oligodendrocyte glycoprotein (35-55)) | Recent Studies (post-2010) (myelin oligodendrocyte glycoprotein (35-55)) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 744 | 2 | 458 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borey, AJ; Clark, JD; Cui, J; Donahue, F; Han, L; Hassan-Zahraee, M; Leach, MW; Lee, KL; Marusic, S; McKew, JC; Pelker, JW; Shen, MW; Shimizu, T; Stedman, NL; Thakker, P; Wolf, SF; Xu, X | 1 |
1 other study(ies) available for naproxen and myelin oligodendrocyte glycoprotein (35-55)
| Article | Year |
|---|---|
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Topics: Analysis of Variance; Animals; Benzoates; Cell Proliferation; Cells, Cultured; Cyclooxygenase Inhibitors; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Female; Glycoproteins; Group IV Phospholipases A2; Hydroxyurea; Lipoxygenase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Myelin-Oligodendrocyte Glycoprotein; Naproxen; Peptide Fragments; Severity of Illness Index; Seveso Accidental Release; Sulfonamides; Th1 Cells; Time Factors | 2008 |